Author: Sumita Paul

Lakewood-Amedex’s Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022   SARASOTA, Fla., April 5, 2022 - Lakewood-Amedex, Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics...

Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors   SARASOTA, Fla., January 25, 2022 — Lakewood-Amedex Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins®, today announced that two new...

Appoints Sumita Paul, MD, MPH, MBA Chief Medical Officer & SVP R&D Appoints Additional Senior Management to its Scientific-Clinical Team   SARASOTA, Fla., January 19, 2022 — Lakewood-Amedex Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called...